BRAF and melanoma: In our experience, both TT and IT groups presented similar baseline characteristics, except for a higher percentage of mucosal melanoma in the IT group (due to a lower incidence of BRAF mutations in this subset) and a higher number of SNLB performed in the BRAF-positive group, as the IT-treated group included stage IV-NED patients typically not requiring this procedure.